HuidaGene Therapeutics ("HuidaGene"), a global clinical-stage biotechnology company pioneering CRISPR-based programmable genome medicines, today announced the appointment of Dr. TJ Cradick as Chief ...
A study reveals that CRISPR gene editing can disable a mutation in melanoma cells that leads to treatment resistance. By targeting the NRAS gene mutation, researchers restored the cells' sensitivity ...
The scientists used CRISPR gene editing tools to disable the mutation and restore treatment sensitivity to the cancer cells in a way that appears to minimize risks of dangerous side effects.
Study finds CRISPR restores the ability for cancer treatments to attack melanoma cancer cells with precision-guided gene edit that ignores healthy cells Wilmington, DE, OCTOBER 15, 2024 -- In a ...